Lv21
120 积分 2023-04-20 加入
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
4小时前
待确认
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
4小时前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
4小时前
已完结
Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study
3天前
已完结
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development
6天前
已完结
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
1个月前
已完结
Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta‐analysis of real‐world evidence
2个月前
已完结
Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis
3个月前
已完结
TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial
3个月前
已完结
Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS–Kaposi’s sarcoma
3个月前
已完结
皖公网安备34019202002308
